KPV targeted oral delivery
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.
Xiao B et al. · Molecular Therapy
Study record
- Population
Eight-week-old male FVB mice; five/group in Figure 7. Separate cell and tracer experiments.
Read source · Full-text reportMethods — Induction of UC mouse model; Figure 7- Formulation
KareBay KPV in PLGA nanoparticles, with or without hyaluronic-acid functionalization, embedded in chitosan/alginate hydrogel.
Read source · Full-text reportMaterials; Fabrication of HA-KPV-NPs- Route
Oral gavage in mice.
Read source · Full-text reportMethods — Induction of UC mouse model- Dose & frequency
16 μg/kg KPV per day in the experimental formulation; no human or KLOW regimen. Tracer doses are separate.
Read source · Full-text reportMethods — Induction of UC mouse model- Study design
DSS-colitis experiment comparing nanoparticle formulations with disease and healthy controls.
Read source · Full-text reportFigure 7; Methods — Induction of UC mouse model- Duration
Efficacy methods: eight days of 3% DSS, five treatment days. Figure 7 caption instead says six treatment days; unresolved.
Read source · Full-text reportMethods — Induction of UC mouse model; Figure 7F- Reported findings
Improved recovery and inflammatory measures; MPO difference between nanoparticle formulations was not statistically significant.
Read source · Full-text reportResults — Promoted therapeutic efficacy; Figure 7- Adverse events
Cell viability assays do not establish human or long-term safety.
Read source · Full-text reportMethods — Biocompatibility of NPs- Monitoring
Daily weight/symptoms; terminal tissue, spleen, colon, MPO and RNA assessments.
Read source · Full-text reportMethods — Induction of UC mouse model
What it supports
Formulation-specific preclinical delivery research.
What it does not establish
No human or KLOW trial. Treatment-duration discrepancy retained; no human cycling inference.
Funding
VA, NIH and Chinese public research grants; no conflicts declared.
Literature search cutoff: 2026-09-08 · Not independently clinically reviewed
Browse study library